Expand IMNN Menu
IMNN MENU

IMNN Latest Press Releases

-- July 21, 2026 --

IMUNON Reports Positive Phase 2 MRD Clinical Data for IMNN-001, Demonstrating the Successful Overcoming of Historical IL-12 Safety Barriers in Frontline Ovarian Cancer Globe Newswire 9:00 AM

-- June 26, 2026 --

Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing Globe Newswire 8:35 AM

-- June 23, 2026 --

Life Sciences Virtual Investor Forum Agenda Announced for June 24th & 25th Globe Newswire 8:35 AM
IMUNON Announces Data Monitoring Committee Recommends Continuation of Phase 3 OVATION 3 Study Without Modification Globe Newswire 8:00 AM

-- June 22, 2026 --

IMUNON to Present at the Life Sciences Investor Forum on June 25th Globe Newswire 4:15 PM

-- June 4, 2026 --

IMUNON Announces Up to $10 Million Cash Financing Globe Newswire 8:00 AM

-- May 12, 2026 --

IMUNON Reports First Quarter 2026 Financial Results and Provides Business Update Globe Newswire 8:00 AM

-- May 5, 2026 --

IMUNON to Hold First Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, May 12, 2026 Globe Newswire 8:30 AM

-- March 31, 2026 --

IMUNON Reports 2025 Financial Results and Provides Business Update Highlighting Significant Progress with Pivotal Phase 3 Study Globe Newswire 8:00 AM

-- March 25, 2026 --

IMUNON Reports Updated Phase 2 Data Showing Continued Improvement in Median Overall Survival with IMNN-001 in Women with Newly Diagnosed Advanced Ovarian Cancer Globe Newswire 8:05 AM

-- March 24, 2026 --

IMUNON to Hold 2025 Financial Results and Business Update Conference Call on Tuesday, March 31, 2026 Globe Newswire 8:00 AM
Market Data Delayed 15 Minutes